Supplier to Physiotherapists, General Public, the NHS & Armed Forces

Hepatitis C Virus: The Next Epidemic, An issue of Gastroenterology Clinics of North America

Not rated yet
0
There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.
51   – Reward points
Availability: MD - Manufactured on demand
    • 20% off
    £63.99, save £12.80
  • £51.19
Qty:  
  • Shipping info

    Our publishing partner, Elsevier, maintains a flat fee for shipping. Books are delivered in the UK via DHL and will require a signature upon delivery.

    The standard delivery time within the UK is 2 working days from the date of invoice.

    Manufactured on demand titles (Availability: MD) take an extra 3-5 working days.

    At this time we only ship Elsevier book orders to addresses within the UK.

    Brexit: We have been informed that some couriers are now charging additional fees for importing from the UK into the EU. The customer is responsible for the payment of any import duties that are in addition to the shipping costs already charged.

  • Payment methods

    logos-payments-tab_1.png

There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.
    • SKU
      9780323402484
    • UPC/ISBN
      9780323402484
    • Stock Last Checked
      Feb 21, 2024
  • Manufacturer
    Elsevier
  • Publication Date
    Dec 22, 2015

Your Elsevier book orders are actioned within 48hrs during the working week. If any one item in your purchase is delayed we will send you what is in stock and will send on the remainder as soon as it arrives. This is provided at no additional shipping cost to you. Stock availability levels are updated on a daily basis.  We ship directly from a UK warehouse.

Manufactured on demand titles (Availability: MD) take an extra 3-5 working days.

Shipping Costs

We currently maintain a flat fee structure for shipping book titles from Elsevier. Buy as many Elsevier titles as you like the we will still charge you the same single item shipping fee.

Overview Delivery Methods

Books are delivered in the UK via DHL and will require a signature upon delivery.

Deliveries within the UK

  • The standard delivery time within the UK is 2 working days from the date of invoice.
  • Print on demand titles take 3-5 working days.

Where is my order? Order Tracking

To find out more information about your order, select from the relevant options below:

Deliveries to the UK and UK shippers

Your order should be delivered to you/your shipper within 2-3 working days.

To track any deliveries using DPD, click here.

If your order is for a print on demand title, your delivery time will be longer, please allow an extra 3-5 working days.

Customer reviews
There are no comments yet. Be the first to leave a comment
Please sign in to add review

We accept the following payment methods: